Compare Abbott Laboratories (ABT) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs MGM Resorts International — how do they compare? Abbott Laboratories trades at $110.97 (market cap $187.95B), while MGM Resorts International trades at $44.5 (market cap $11.10B). The key difference: Abbott Laboratories is far larger — about 16.9× MGM Resorts International's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | MGM | |
|---|---|---|
Market Cap | $187.95B | $11.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $50.69 |
52-Week Low | $82.57 | $30.72 |
Enterprise Value | $214.96B | $38.40B |
Dividend Yield | 2.32% | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
MGM Resorts International (MGM) trades at $43.915, up 1.28% on the day, with a bearish technical signal and neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.59 per share versus $0.63 expected, though revenue hit a record. The company faces a shareholder investigation into Barry Diller's proposed acquisition at $48.30 per share. Fundamentals show a P/E of 26.75 and net income margin of 2.4%, with revenue growth to $17.54B in 2025.
The outlook is mixed: analyst consensus targets $51.14 with 49% buy ratings, but technicals and acquisition uncertainty pose risks. Upside hinges on Las Vegas recovery and BetMGM's iGaming expansion, while margin pressures and legal probes are headwinds. Cash flow trends improved to a projected net positive $572M in 2026, supporting stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
